BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Creese B, Bell E, Johar I, Francis P, Ballard C, Aarsland D. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. Am J Med Genet 2018;177:232-41. [DOI: 10.1002/ajmg.b.32549] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Agüera-Ortiz L, Babulal GM, Bruneau MA, Creese B, D'Antonio F, Fischer CE, Gatchel JR, Ismail Z, Kumar S, McGeown WJ, Mortby ME, Nuñez NA, de Oliveira FF, Pereiro AX, Ravona-Springer R, Rouse HJ, Wang H, Lanctôt KL. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. J Alzheimers Dis 2022. [PMID: 35786651 DOI: 10.3233/JAD-215483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zheng W, Fan D. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications. Front Aging Neurosci 2022;14:851135. [DOI: 10.3389/fnagi.2022.851135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, Ballard C. Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities. Nat Rev Neurol 2022. [PMID: 34983978 DOI: 10.1038/s41582-021-00597-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
4 Lim JL, Lohmann K, Tan AH, Tay YW, Ibrahim KA, Abdul Aziz Z, Mawardi AS, Puvanarajah SD, Lim TT, Looi I, Ooi JCE, Chia YK, Muthusamy KA, Bauer P, Rolfs A, Klein C, Ahmad-Annuar A, Lim SY. Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson's disease: mutational spectrum and clinical features. J Neural Transm (Vienna) 2021. [PMID: 34779914 DOI: 10.1007/s00702-021-02421-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology 2021;202:108822. [PMID: 34626666 DOI: 10.1016/j.neuropharm.2021.108822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
6 Dumitrascu DL. Gaucher disease: an update. Med Pharm Rep 2021;94:S54-6. [PMID: 34527912 DOI: 10.15386/mpr-2231] [Reference Citation Analysis]
7 Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behav Sci (Basel) 2021;11:74. [PMID: 34068064 DOI: 10.3390/bs11050074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sucunza D, Rico AJ, Roda E, Collantes M, González-Aseguinolaza G, Rodríguez-Pérez AI, Peñuelas I, Vázquez A, Labandeira-García JL, Broccoli V, Lanciego JL. Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques. Int J Mol Sci 2021;22:4825. [PMID: 34062940 DOI: 10.3390/ijms22094825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Senkevich KA, Kopytova AE, Usenko TS, Emelyanov AK, Pchelina SN. Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae 2021;13:70-8. [PMID: 34377557 DOI: 10.32607/actanaturae.11031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 den Heijer JM, van Hilten JJ, Kievit AJA, Bonifati V, Groeneveld GJ. Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. Mov Disord Clin Pract 2021;8:33-6. [PMID: 33426156 DOI: 10.1002/mdc3.13098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu X, Le W. Profiling Non-motor Symptoms in Monogenic Parkinson's Disease. Front Aging Neurosci 2020;12:591183. [PMID: 33192488 DOI: 10.3389/fnagi.2020.591183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jäger C, Hodak Z, Lohmann K, Ma Y, Eidelberg D, Timmermann L, Hiller K, Tittgemeyer M, Drzezga A, Diederich N, Eggers C. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Mov Disord 2020;35:2201-10. [PMID: 32853481 DOI: 10.1002/mds.28225] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
13 Ryan E, Seehra G, Sharma P, Sidransky E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 2019;32:589-96. [PMID: 31188151 DOI: 10.1097/WCO.0000000000000715] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
14 Tantawy AAG, Adly AAM, Abdeen MSED, Salah NY. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients. Neurogenetics 2020;21:159-67. [DOI: 10.1007/s10048-020-00607-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Rossi M, Farcy N, Starkstein SE, Merello M. Nosology and Phenomenology of Psychosis in Movement Disorders. Mov Disord Clin Pract 2020;7:140-53. [PMID: 32071931 DOI: 10.1002/mdc3.12882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Piredda R, Desmarais P, Masellis M, Gasca‐salas C. Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review. Eur J Neurol 2019;27:229-34. [DOI: 10.1111/ene.14115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hansen D, Ling H, Lashley T, Holton JL, Warner TT. Review: Clinical, neuropathological and genetic features of Lewy body dementias. Neuropathol Appl Neurobiol 2019;45:635-54. [PMID: 30977926 DOI: 10.1111/nan.12554] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
18 Senkevich KA, Miliukhina IV, Pchelina SN. [The genetic predictors of cognitive impairment in Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:109-17. [PMID: 30251988 DOI: 10.17116/jnevro2018118081109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Mishra A, Krishnamurthy S. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson’s Model in Rats. Neurotox Res 2019;35:542-62. [DOI: 10.1007/s12640-018-9983-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
20 Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Mov Disord 2019;34:9-21. [PMID: 30589955 DOI: 10.1002/mds.27583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
21 Zhang Y, Shu L, Zhou X, Pan H, Xu Q, Guo J, Tang B, Sun Q. A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease. Parkinsons Dis 2018;2018:3136415. [PMID: 30363648 DOI: 10.1155/2018/3136415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
22 Orme T, Guerreiro R, Bras J. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. Curr Neurol Neurosci Rep 2018;18:67. [PMID: 30097731 DOI: 10.1007/s11910-018-0874-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
23 Mishra A, Chandravanshi LP, Trigun SK, Krishnamurthy S. Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms. Biochem Pharmacol 2018;155:479-93. [PMID: 30040928 DOI: 10.1016/j.bcp.2018.07.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
24 Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med 2018;16:34. [PMID: 29510692 DOI: 10.1186/s12916-018-1016-8] [Cited by in Crossref: 99] [Cited by in F6Publishing: 129] [Article Influence: 24.8] [Reference Citation Analysis]
25 Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018;125:615-650. [PMID: 29222591 DOI: 10.1007/s00702-017-1821-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 106] [Article Influence: 18.6] [Reference Citation Analysis]